Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells

European Journal of Pharmacology

Volumn 637, Issue 1-3, 2010, Pages 38-45

  Moody, Terry W ^a   Berna, Marc J ^b   Mantey, Samuel ^b   Sancho, Veronica ^b   Ridnour, Lisa ^a   Wink, David A ^a   Chan, Daniel ^c   Giaccone, Giuseppe ^a   Jensen, Robert T ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor; Lung cancer; Neuromedin B; Reactive oxygen species; Transactivation

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GASTRIN RELEASING PEPTIDE RECEPTOR; GEFITINIB; NEUROMEDIN B; NEUROPEPTIDE RECEPTOR; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; CANCER CELL; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CELL SIZE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GROWTH INHIBITION; IC 50; LUNG NON SMALL CELL CANCER; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TRANSACTIVATION;

ACETYLCYSTEINE; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME INHIBITORS; HUMANS; NEUROKININ B; PHOSPHORYLATION; PHOSPHOTYROSINE; QUINAZOLINES; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, BOMBESIN; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

EID: 77953288763     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.057     Document Type: Article

References (40)

1. 2) receptor antagonist. Bioorg. Med. Chem. 1998, 8:2589-2594.
2. Bae Y.S., Kang S.W., Seo M.S., Baines I.C., Tekle E., Chock P.B., Rhee S.G. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J. Biol. Chem. 1997, 272:217-221.
3. Benya R.V., Wada E., Battey J.F., Fathi Z., Wang L.H., Mantey S.A., Coy D.H., Jensen R.T. Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol. Pharmacol. 1992, 42:1058-1068.
4. Cheng-Hsien C., Yung-Ho H., Yuh-Mou S., Chun-Cheng H., Horng-Mo L., Huei-Mei H., Tso-Hsiao C. Src homology 2-containing phosphotyrosine phosphatase regulates endothelin-1-induced epidermal growth factor receptor transactivation in rat renal tubular cell NRK-52E. Pflugers Arch. 2006, 452:16-24.
5. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
6. Corjay M.H., Dobrzanski D.J., Way J.M., Viallet J., Shapira H., Worland P., Sausville E.A., Battey J.F. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J. Biol. Chem. 1991, 266:18771-18779.
7. Cuttitta F., Carney D.N., Mulshine J., Moody T.W., Fedorko J., Fischler A., Minna J.D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer cells. Nature 1985, 316:823-826.
8. Das A.K., Sato M., Story M.D., Peyton M., Graves R., Redpath S., Girard L., Gazdar A.F., Shay J.W., Minna J.D., Nirodi C.S. Non-small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res. 2006, 66:9601-9608.
9. Fathi Z., Way J.W., Corjay M.H., Viallet J., Sausville E.A., Battey J.F. Bombesin receptor structure and expression in human lung carcinoma cell lines. J. Cell Biochem. Suppl. 1996, 24:237-246.
10. Giaccone G., Battey J., Gazdar A.F., Oie H., Draoui M., Moody T.W. Neuromedin B is present in lung cancer cell lines. Cancer Res. 1992, 52:2732s-2736s.
11. Helfrich B.A., Raben D., Varella-Garcia M., Gustafson D., Chan D.C., Bemis L., Coldren C., Baron A., Zeng C., Franklin W.A., Hirsch F.R., Gazdar A.F., Minna J., Bunn P.A. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin. Cancer Res. 2006, 12:7117-7125.
12. Janmaat M.L., Kruyt F.A., Rodriguez J.A., Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 2003, 9:2316-2326.
13. Jensen R.T., Moody T.W. Bombesin-related peptides and neurotensin: effects on cancer growth/proliferation and cellular signaling in cancer. Handbook of Biologically Active Peptides 2006, 429-434. Elsevier, Amsterdam. A. Kastin (Ed.).
14. Jensen J.A., Carroll R.E., Benya R.V. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001, 22:689-699.
15. Jensen R.T., Battey J.F., Spindel E.R., Benya R.V. International union of pharmacology. LVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol. Rev. 2008, 60:1-42.
16. Lach E.B., Broad S., Rozengurt E. Mitogenic signaling by transfected neuromedin B receptors in Rat-1 cells. Cell Growth Differ 1995, 6:1427-1435.
17. Lango M.N., Dyer K.F., Lui V.W., Gooding W.E., Gubish C., Siegfried J.M., Grandis J.R. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J. Natl. Cancer Inst. 2002, 94:375-383.
18. Liu X., Carlisle D.L., Swick M.C., Gaither-Davis A., Grandis J.R., Siegfried J.M. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Exp. Cell Res. 2007, 313:1361-1372.
19. Lui V.W., Thomas S.M., Zhang Q., Wentzel A.M., Siegfried J.M., Li J.Y., Grandis J.R. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 2003, 22:6183-6193.
20. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Louis D.N., Christiani D.C., Setteman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
21. Mantey S.A., Weber H.C., Sainz E., Akeson M., Ryan R.R., Pradhan T.K., Searles R.P., Spindel E.R., Battey J.F., Coy D.H., Jensen R.T. Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates it has a unique pharmacology compared to other mammalian bombesin receptors. J. Biol. Chem. 1997, 272:26062-26071.
22. Moody T.W., Staley J., Zia F., Coy D.H., Jensen R.T. Neuromedin B binds with high affinity, elevates cytosolic calcium and stimulates the growth of small cell lung cancer cell lines. J. Pharmacol. Exp. Ther. 1992, 263:311-317.
23. Moody T.W., Venugopal R., Hu V., Gozes Y., McDermed J., Leban J.J. BW 1023U90: a new GRP receptor antagonist for small-cell lung cancer cells. Peptides 1996, 17:1337-1343.
24. Moody T.W., Jensen R.T., Garcia L., Leyton J. Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells. Eur. J. Pharmacol. 2000, 409:133-142.
25. Moody T.W., Mantey S.A., Pradhan T.K., Schumann M., Nakagawa T., Martinez A., Jensen R.T. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J. Biol. Chem. 2004, 279:23580-23589.
26. Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., Fujii T., Kuwano M. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 2004, 3:465-472.
27. Paez J.G., Janne P.A., Lee J.C., Tracey S., Greulich H., Gabriel S., Herman P., Kaye F.J., Linderman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
28. Patel O., Shulkes A., Baldwin G.S. Gastrin-releasing peptide and cancer. Biochim. Biophys. Acta 2006, 1766:23-41.
29. Reubi J.C., Wenger S., Schumuckli-Maurer J., Schaer J.C., Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin (6-14). Clin. Cancer Res. 2002, 8:1139-1146.
30. Ryan R.R., Katsuno T., Mantey S.A., Pradhan T.P., Weber H.C., Battey J.F., Jensen R.T. Comparative pharmacology of a nonpeptoid neuromedin B antagonist PD 168368. J. Pharmacol. Exp. Ther. 1999, 290:1202-1211.
31. Santiskulvong C., Rozengurt E. Galardin (GM 6001), a broad-spectrum matrix metalloproteinase inhibitor, blocks bombesin- and LPA-induced EGF receptor transactivation and DNA synthesis in rat-1 cells. Exp. Cell Res. 2003, 290:437-446.
32. Schafer B., Gschwind A., Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004, 23:991-999.
33. Siegfried J.M., Krishnamachary N., Davis A.G., Gubish C., Hunt J.D., Shriver S.P. Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm. Pharmacol. Ther. 1999, 12:291-302.
34. Thomas S.M., Grandis J.R., Wentzel A.L., Gooding W.E., Lui V.W., Siegfried J.M. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia 2005, 7:426-431.
35. Touyz R.M., Cruzado M., Tabet F., Yao G., Salomon S., Schiffrin E.L. Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation. Can. J. Physiol. Pharmacol. 2003, 81:159-167.
36. Ushio-Fukai M., Griendling K.K., Becker P.L., Hilenski L., Halleran S., Alexander R.W. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2001, 21:489-495.
37. Witta S.E., Gemmill R.M., Hirsch F.R., Coldren C.D., Hedman K., Ravdel L., Helfrich B., Dziadziuszko R., Chan D.C., Sugita M., Chan Z., Baron A., Franklin W., Drabkin H.A., Girard L., Gazdar A.F., Minna J.B., Bunn P.A. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006, 66:944-950.
38. Xiao D., Qu X., Weber H.C. Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell Signal. 2003, 15:945-953.
39. Zhang Q., Thomas S.M., Smithgall T.E., Siegfried J.M., Kamens J., Gooding W.E., Grandis J.R. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res. 2004, 64:6166-6173.
40. Zhang Q., Bhola N.E., Lui V.W., Siwak D.R., Thomas S.M., Gubish C.T., Siegfried J.M., Mills G.B., Shin D., Grandis J.R. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol. Cancer Ther. 2007, 6:1414-1424.